A randomized, comparative investigator-initiated clinical trial to verify the efficacy of the therapeutic radiopharmaceutical 64Cu-ATSM for recurrent malignant glioma (STEP-64)
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs 64Cu diacetyl bis (N4 methylthiosemicarbazone) (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- Acronyms NCCH2301 exam; STEP-64; STEP-64 trial
- 04 Feb 2025 New trial record